Ask AI
ProCE Banner Activity

CheckMate 8HW: Expanded Analyses in Patients With Centrally Confirmed MSI-H/dMMR mCRC From the Phase III Trial of Nivolumab + Ipilimumab vs Nivolumab or Chemotherapy

Conference Coverage
Slideset

In patients with centrally confirmed MSI-H/dMMR mCRC, nivolumab plus ipilimumab demonstrated improved PFS and PFS2 vs chemotherapy in the first-line setting and improved PFS and PFS2 vs nivolumab across all lines of therapy in an expanded analysis of the phase III CheckMate 8HW trial.

Released: June 09, 2025

Expiration: December 08, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group